



**Governing Council  
Sixty-eighth Session**

**GC/68/14**  
23 April 2026

*Lyon, 27–28 May 2026*  
*Hybrid format*

## APPOINTMENT OF NEW MEMBERS OF THE SCIENTIFIC COUNCIL

1. In accordance with Article VI of the Statute and Resolutions [GC/60/R19](#) and [GC/63/R13](#), the term of office of two members of the Scientific Council, namely Drs Jie He (China) and Kazem Zendeheel (Islamic Republic of Iran) were completed with the 2022 and 2026 meetings of the Governing Council, respectively.
2. In accordance with Article VI of the Statute and Resolutions and [GC/67/R14](#), the term of office of five members of the Scientific Council, namely, Henrik Hjalgrim (Denmark), Sirpa Heinävaara (Finland), Valery Lemmens (Netherlands), Ben Spycher (Switzerland) and Satish Gopal (United States of America) will be completed with the 2026 meeting of the Governing Council.
3. For the information of the Council, this leaves the following 23 members (6 women and 17 men) still serving on the Scientific Council: Drs Mohamed Berraho (Morocco), Valeriy V. Breder (Russian Federation), Roberta De Angelis (Italy), David Gisselsson Nord (Sweden), André Karch (Germany), István Kenessey (Hungary), Young-Woo Kim (Republic of Korea), Prashant Mathur (India), Pål Romundstad (Norway) and Orla Shiels (Ireland) until 2027; Drs Adam Grant Elshaug (Australia), Eric Van Cutsem (Belgium), Hesham Elghazaly (Egypt), Tatsuhiro Shibata (Japan), Ali Saeed Al-Zahrani (Saudi Arabia), María José Sánchez Pérez (Spain) and Richard Sullivan (United Kingdom) until 2028; and Drs Eva Scherhammer (Austria), Mariana Emerenciano (Brazil), Rayjean Hung (Canada), Robert Barouki (France), Lúcio José de Lara Santos (Portugal) and Mohamad Ussama Alhomsí (Qatar) until 2029.
4. The areas of expertise of those members remaining on the Scientific Council are provided below for consideration by the Governing Council in making its selection of new Scientific Council members from among the nominations.

| Name               | Country | Term of office | Gender | Field of expertise  |
|--------------------|---------|----------------|--------|---|
| Dr Mohamed Berraho | Morocco | 2024 – 2027    | M      | Cancer Epidemiology, epidemiology of cervical cancer, epidemiology of noncommunicable diseases (diabetes and hypertension), Epidemiology of NCD risk factors, mental health, occupational health. |

| <b>Name</b>                     | <b>Country</b>     | <b>Term of office</b> | <b>Gender</b> | <b>Field of expertise</b>   |
|---------------------------------|--------------------|-----------------------|---------------|---|
| Dr Valeriy V. Breder            | Russian Federation | 2024 – 2027           | M             | Liver cancer: screening, early diagnosis, cancer treatment.<br>Lung cancer: chemotherapy, immunotherapy, targeted therapy.  |
| Dr Roberta De Angelis           | Italy              | 2024 – 2027           | F             | Descriptive and analytical cancer epidemiology; cancer registries; biostatistics; statistical methods to derive cancer burden and outcome indicators from population-based data.    |
| Professor David Gisselsson Nord | Sweden             | 2024 – 2027           | M             | Genomics, childhood cancer, implementation of precision medicine, computational carcinogenesis, laboratory establishment in low-income countries.                                   |
| Professor André Karch           | Germany            | 2024 – 2027           | M             | Causal inference in observational research, mammography screening, breast cancer, clinical epidemiology, biomarkers, statistical and epidemiological methods.                       |
| Professor István Kenessey       | Hungary            | 2024 – 2027           | M             | Epidemiology of cancer, cancer survivorship and the effect of advanced oncological therapies.   |
| Professor Young-Woo Kim         | Republic of Korea  | 2024 – 2027           | M             | Surgical oncology (gastric cancer); translational research (proteogenomics and drug development); medical engineering for surgical device development and patient blood management. |
| Professor Prashant Mathur       | India              | 2024 – 2027           | M             | Noncommunicable diseases, epidemiology and surveillance (including cancer), cancer registrations, cancer risk reduction strategies.   |
| Professor Pål Romundstad        | Norway             | 2024 – 2027           | M             | Cancer epidemiology, reproductive epidemiology, mendelian randomization, life course and intergenerational studies.   |
| Professor Orla Sheils           | Ireland            | 2024 – 2027           | F             | Molecular pathology; molecular diagnostic assays; translational research; virally driven cancers; cancer prevention, detection, diagnosis, and treatment.                           |

| <b>Name</b>                  | <b>Country</b>          | <b>Term of office</b> | <b>Gender</b> | <b>Field of expertise</b>   |
|------------------------------|-------------------------|-----------------------|---------------|---|
| Professor Adam Grant Elshaug | Australia               | 2025 – 2028           | M             | Health policy (development, implementation, evaluation), health technology assessment and coverage, health economics and (clinical) epidemiology  |
| Professor Eric Van Cutsem    | Belgium                 | 2025 – 2028           | M             | Gastrointestinal and Digestive cancers (colorectal, gastric, pancreas, bile duct, esophageal cancer and neuroendocrine tumors),   |
| Professor Hesham Elghazaly   | Egypt                   | 2025 – 2028           | M             | Breast Cancer-GIT Malignancies - Lung Cancer  |
| Professor Tatsuhiro Shibata  | Japan                   | 2025 – 2028           | M             | Cancer genomics, tumour pathology, bioinformatics   |
| Dr Ali Saeed Al-Zahrani      | Kingdom of Saudi Arabia | 2025 – 2028           | M             | Cancer and Genetic Epidemiology, National Cancer Control and Prevention Strategy, Public Health Policy, Population Based Cancer Registration, Cancer Screening and Early Detection  |
| Dr María José Sánchez Pérez  | Spain                   | 2025 – 2028           | F             | Epidemiological studies and research projects related to the aetiology; patterns of care, and survival of cancer patients. Cancer epidemiology, cancer prevention (lifestyle, diet & nutrition) and control; EPIC coordinator |
| Professor Richard Sullivan   | United Kingdom          | 2025 – 2028           | M             | Health economics, early detection (breast, cervix and oral cancer) lung cancer, global cancer surgery, cancer control (in particular populations impacted by insecurity and conflicts).                                       |

| Name                                    | Country | Term of office | Gender | Field of expertise  |
|---|---------|----------------|--------|---|
| Professor Eva Schernhammer              | Austria | 2026-2029      | F      | Influence of lifestyle, including diet, and environmental risk factors to chronic diseases and longevity in humans;<br>Osteoporotic Fractures in Men;<br>Biorepositories;<br>Lifestyle and environmental risk factors on mortality and various aging related outcomes including cardiovascular disease, diabetes, and cognitive function.<br>Aetiology and prevention of gastrointestinal tumours, including the chemo preventive effects of COX-2 inhibitors and methyl donors on cancer risk. |
| Dr Mariana Emerenciano Cavalcanti de Sá | Brazil  | 2026-2029      | F      | Biological Sciences / Area: General Biology / Subarea: Biologia Molecular.<br>Health Sciences / Area: Medicine / Subarea: Clínica Médica / Specialty: Cancerologia<br>Biological Sciences / Area: Genetics / Subarea: Genética Molecular  |
| Dr Rayjean Hung                         | Canada  | 2026-2029      | F      | Cancer epidemiology<br>Adult aerodigestive tract cancers and pediatric tumours focusing on cancer etiology, early detection, prognosis and risk prediction modelling<br>Multi-modal data elements and data harmonization<br>Omics discovery; Policy implementation  |
| Professor Robert Barouki                | France  | 2026-2029      | M      | Biochemistry, molecular biology<br>Chemical toxicants exposure, genotoxicity<br>Pollutants and cancer   |

| Name                                | Country  | Term of office | Gender | Field of expertise   |
|-------------------------------------|----------|----------------|--------|--|
| Professor Lúcio José de Lara Santos | Portugal | 2026-2029      | M      | Surgical oncology, experimental pathology, clinical research, carcinogenesis;<br>Neglected cancer-related diseases, translational medicine, pre-clinical studies;<br>Cancer registries and cancer-related infections;<br>Prehabilitation of surgical oncology patients |
| Professor Mohamad Ussama Alhomsi    | Qatar    | 2026-2029      | M      | Hematology, oncology   |

5. In accordance with Article VI.2 of the Agency's Statute, the Governing Council is requested to select new members to be appointed to the Scientific Council from the attached list of experts, one each from China, Denmark, Finland, Netherlands, Iran (Islamic Republic of), Switzerland and United States of America.

| CHINA  |  |
|--|--|
| <p><b>Dr Jie He</b><br/>                     National Cancer Center of China<br/> <b>Field:</b> Thoracic cancer surgery, translational research of thoracic cancers, early screening and prevention.</p>   |  |
| DENMARK  |  |
| <p><b>Professor Henrik Hjalgrim</b><br/>                     Danish Cancer Institute, Copenhagen<br/> <b>Field:</b> Haematology, Childhood oncology, pathology and immunology; Epidemiology, biostatistics, genetics, and bioinformatics<br/><br/>                     Prenatal and early life exposures, e.g. infections, and immune-related conditions in childhood cancers and haematological malignancies.</p> |  |

|   |   |
|---|---|
| <b>FINLAND</b>  |   |
| <p><b>Professor Peeter KARIHTALA</b><br/>Helsinki University<br/><b>Field:</b><br/>Breast cancer and treatment of breast cancer, translational and epidemiological breast cancer studies.<br/>Medical oncology and clinical trials.</p> |   |
| <b>NETHERLANDS</b>  |   |
| <p><b>Professor Carla Henrica van Gils</b><br/>Dutch Cancer Society<br/><b>Field:</b><br/>Clinical epidemiology of cancer</p>   | <p><b>Dr Gijs Geleijnse</b><br/>Norwegian Institute of Public Health<br/><b>Field:</b><br/>Cancer Registries, cancer surveillance and data-driven innovation; public health, Artificial Intelligence applications in healthcare</p> |
| <b>SWITZERLAND</b>  |   |
| <p><b>Dr Eliane Rohner</b><br/>University of Bern<br/><b>Field:</b><br/>Cancer epidemiology and biostatistics; Cervical cancer prevention; HIV incidence on cancer treatments; Childhood cancer</p>                                     | <p><b>Dr Jean-Luc Bulliard</b><br/>University of Lausanne<br/><b>Field:</b> Cancer epidemiology; Health data science; lung and colorectal cancer screening; Public Health.</p>  |
| <b>Iran (Islamic Republic of)</b>   |   |
| <i>Yet to be received</i>   |   |
| <b>United States of America</b>   |   |
| <i>Yet to be received</i>   |   |

NB: The *curricula vitae* will be distributed to Governing Council members only.